Acetylcholinesterase inhibitors in alzheimer's disease: Further comments on their mechanisms of action and therapeutic consequences;Les anticholinesterasiques dans la maladie d'alzheimer: Réflexions sur leurs modalités d'action potentielles et les effets thérapeutiques

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 8, Issue 2, 2010, Pages 123-131

  Nieoullon, Andre ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Donepezil; Galantamine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR;

AGED; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; PATHOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SYNAPSE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARASYMPATHETIC NERVOUS SYSTEM; RECEPTORS, NICOTINIC; SYNAPSES;

EID: 77953495128     PISSN: 17601703     EISSN: 19506988     Source Type: Journal    
DOI: 10.1684/pnv.2010.0208     Document Type: Article

References (38)

1. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase in necropsy brain tissue. J Neurol Sci 1977;34:247-65.
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
3. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Piggott M, Haroutunian V, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000;393:215-22.
4. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapy. Life Sci 1995;56:869-76.
5. Power A. Slow-wave sleep, acetylcholine, and memory consolidation. Proc Natl Acad Sci USA 2004;101:1795-6.
6. Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H, et al. Pharmacology of Alzheimer's disease: appraisal and prospects. Dement Geriatr Cog Disord 2005;19:229-45.
7. Nieoullon A, Bentué-Ferrer D, Bordet R, Tsolaki M, Forstl H. Importance of circadian rythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Curr Med Res Opin 2008;24:3357-67.
8. Davis B, Sadik K. Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disord 2006;21:120-9.
9. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttimes sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr Med Opin 2004;20:517-24.
10. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Bt J Psychiatry 1989;154:797-800.
11. Shapira M, Tur-Kaspa I, Bosgraaf, Livni N, Grant AD, Grisaru et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet 2000;9:1273-81.
12. Nieoullon A. Neurobiologie cellulaire et fonctionnelle. Aspects neurochimiques. Encyclopédie Médico-Chirurgicale, Neurologie. Paris: Elsevier, 1994: 17-003-A-10.
13. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
14. Liang YQ, Tang XC. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 2006;27:1127-36.
15. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M. Direct evidence that release-stimulating a̧7 nicotinic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002;80:1071-8.
16. Kim J, Isokawa M, Ledent C, Alger BE. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 2002;22:10182-91.
17. Soreq H, Seidman S. Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci 2001;2:294-302.
18. Layer PG, Weikert T, Alber R. Cholinesterases regulate neurite outgrowth of chick nerve cells in vitro by means of a nonenzymatic mechanism. Cell Tissue Res 1993;273:219-26.
19. Sternfeld M, Ming G, Song H, Sela K, Timberg R, Poo M, et al. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini. J Neurosci 1998;18:1240-9.
20. De la Escalera S, Bockamp EO, Moya F, Piovant M, Jimenez F. Characterization and gene cloning on neurotactin, a Drosophila transmembrane protein related to cholinesterase. EMBO J 1990;9:3593-601.
21. Lev-Lehman E, Deutsch V, Eldor A, Soreq H. Immature human megakaryocytes produce muclear-associated aceylcholinesterase. Blood 1997;89:3644-53.
22. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998;393:373-7.
23. Relyea RA, Mills N. Predator-induced stress makes the pesticide carbaryl more deadly to gray treefrog tadpoles (Hyla versicolor). Proc Natl Acad Sci USA 2001;98:2491-6.
24. Erb C, Troost J, Kopf S, Schmitt U, Lö ffelholtz K, Soreq H, et al. Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. J Neurochem 2001;77:638-46.
25. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J. Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice. Neurochem Int 2008;52:972-8.
26. Rice SG, Nowak L, Duysen EG, Lockridge O, Lahiri DK, Reyes PF. Neuropathological immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. J Alzheimers Dis 2007;11:481-9.
27. Kikuchi T, Okamura T, Fukushi K, Takahashi K, Toyohara J, Okada M, et al. Cerebral acetylcholinesterase imaging: development of the radioprobes. Curr Top Med Chem 2007;7:1790-9.
28. Wright C, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and pattern of selective vulnerability. Ann Neurol 1993;34:373-84.
29. Beeri R, Le Novere N, Mervis R, Huberman T, Grauer E, Changeux JP, et al. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterasetransgenic mice. J Neurochem 1997;69:2441-51.
30. Sberna G, Saez-Valero J, Li QX, Beyreuther K, Masters CL, Mclean CA, et al. Acetylcholinesterase is increased in the brain of transgenic mice expressing c-terminal fragment (CT100) of the b̃-amyloid protein precursor of Alzheimer's disease. J Neurochem 1998;71:723-31.
31. Nordberg A, Hellstrom-Lindahl E, Almkvist O, Meurling L. Activity of acetylcholinesterase in CSF increases in Alzheimer's patients after treatment with tacrine. Alzheimer's Reports 1999;2:347-52.
32. Dong H, Csernansky CA, Martin MV, Bertchume A, Vallera D, Csernansky JG. Acetylcholinesterase inhibitors ameliorate behavioural deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology 2005;181:145-52.
33. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 2006; 20: S8-11.
34. Kimura M, Komatsu H, Ogura H, Sawada K. Comparison of donepezil and memantine for protective effect against amyloidbeta (1-42) toxicity in rat septal neurons. Neurosci Lett 2005;391:17-21. (Pubitemid 41642670)
35. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998;71:2439-46.
36. Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villaroya M, Garcia AG, et al. Galantamine prevents apoptosis induced by b̃-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004;46:103-14.
37. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. PNAS (USA) 2002;99:12432-7.
38. Nizri E, Wirguin I, Brenner T. The role of choline balance perturbation in neurological diseases. Drug News Perspect 2007;20:421-9.